top of page
  • Recruiting
    • Dec 20, 2019

NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, Oral RAD51 Inhibitor, in B-Cell Malignancies

Updated: May 26, 2022

NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors


cyt-0851

A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors


This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.


Sponsor

Cyteir Therapeutics, Inc

 

ClinicalTrials.gov Identifier: NCT03997968


Official Title: A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors


First Posted : June 25, 2019